An orally-available monovalent SMAC mimetic compound as a broad-spectrum antiviral
作者机构:Tsinghua-Peking Center for Life SciencesBeijing Advanced Innovation Center for Structural BiologyBeijing Frontier Research Center for Biological StructureMOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical BiologySchool of Pharmaceutical SciencesTsinghua UniversityBeijing 100084China Chinese Institutes for Medical ResearchBeijing 100069China Boehringer Ingelheim RCV GmbH&Co KGViennaAustria College of Life Sciences and OceanographyShenzhen UniversityShenzhen 518060China Research Beyond BordersBoehringer IngelheimBiberach an der RissGermany Research Beyond BordersBoehringer IngelheimShanghai 200120China
出 版 物:《Protein & Cell》 (蛋白质与细胞(英文版))
年 卷 期:2024年第15卷第1期
页 面:69-75页
核心收录:
学科分类:0710[理学-生物学] 1007[医学-药学(可授医学、理学学位)] 10[医学]
基 金:supported by grants from the State Key Research Development Program of China to X.T. (2022Y FE0102200 and 2021YFC2300200) the Spring Breeze Fund of Tsinghua University and funding from Boehringer Ingelheim Intermational GmbH.M.M.was supported by a grant from the National Natural Science Foundation of China to M.M. (32100107) the fellowship of China Postdoctoral Science Foundation (2021M691807)
主 题:mortality spectrum compound
摘 要:DearEditor,The coronavirus disease 2019(COVID-19)pandemic caused great global morbidity and mortality concurrent with astronomical socioeconomic damages and *** now,the culpable pathogen,SARS-CoV-2,has infected over 6 hundred million people resulting in more than 6 million deaths worldwide(WHO SARSCoV-2 cases).There is an urgent need for rapid development of effective and affordable therapeutics for COVID-19 patients.